The Michael J. Fox Foundation announced a $5.6-million award to drive a Phase 2 clinical trial to investigate the potential of inosine — a naturally occurring chemical that gives rise to urate in the body — to slow or stop the progression of Parkinson’s disease.

The Michael J. Fox Foundation has opened registration for its annual PD Therapeutics Conference to be held in Chicago, Illinois, on September 15, 2008.

The Michael J. Fox Foundation for Parkinson’s Research seeks applications for its $10-million 2008 Therapeutics Development Initiative. The 2008 program includes a special funding track for academic researchers.

The Michael J. Fox Foundation for Parkinson’s Research announced the launch of a new funding program, Improving Delivery of Parkinson’s Disease Therapeutics to the Brain.

The Foundation has announced a $1-million  new Web-based Clinical Assessment Program to drive the creation and testing of Web-based tools that would allow any patient with a personal computer and an Internet connection to participate in clinical research from the comfort of their own home.

Michael J. Fox Foundation for Parkinson’s Research today announced the 2008 launch of its annual Clinical Intervention Awards.

Four industry research projects targeted as part of innovative Therapeutics Development Initiative.

Approximately $2 million in total funding was awarded to seven research studies aiming to advance the ability of the Parkinson’s research field, and drug makers, to therapeutically target two genes — LRRK2 and alpha-synuclein.

Founding gift for “The Grove Circle,” honoring planned gift donors,
reflects shared commitment to transformative approach

A research team funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative will work to optimize a small interfering RNA (siRNA)-based therapeutic that could slow or stop the progression of Parkinson’s disease by reducing expression of the protein alpha-synuclein.